Hilleman Laboratories will invest around Rs 300 crore in the next four to five years to develop low-cost vaccines to treat diseases like cholera and meningitis. The company is a 50:50 joint venture between MSD Pharmaceuticals and UK-based Wellcome Trust. The company is developing a synthetic vaccine to fight meningitis in Asian, African and Latin American countries.
Hilleman Lab to invest Rs 300 crore to develop low-cost vaccines
Date posted: Saturday 31 October 2015